Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 29, 2018 08:30 ET | Source: Acer Therapeutics Inc.

Acer Therapeutics Submits NDA for EDSIVO™ for the Treatment of vEDS

Requests Priority Review NEWTON, Mass., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and...
September 24, 2018 08:30 ET | Source: Acer Therapeutics Inc.

Acer Therapeutics to Present at the 2018 Cantor Global Healthcare Conference

NEWTON, Mass., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
August 20, 2018 08:30 ET | Source: Acer Therapeutics Inc.

Acer Therapeutics to Present at the 20th Annual H.C. Wainwright Conference

NEWTON, Mass., Aug. 20, 2018 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
August 13, 2018 16:01 ET | Source: Acer Therapeutics Inc.

Acer Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update

Acer continues to progress towards goal of commercializing EDSIVO™ Company appoints VPs of Medical Affairs and Quality NEWTON, Mass., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc....
August 03, 2018 16:01 ET | Source: Acer Therapeutics Inc.

Acer Therapeutics Announces Closing of Underwritten Public Offering

NEWTON, Mass., Aug. 03, 2018 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
August 01, 2018 09:00 ET | Source: Acer Therapeutics Inc.

Acer Therapeutics Announces Pricing of Underwritten Public Offering

NEWTON, Mass., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious...
July 31, 2018 16:01 ET | Source: Acer Therapeutics Inc.

Acer Therapeutics Announces Underwritten Public Offering

NEWTON, Mass., July 31, 2018 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
May 14, 2018 16:01 ET | Source: Acer Therapeutics Inc.

Acer Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update

Acer continues progression from development to potential commercialization of EDSIVO™ Company appoints Chief Legal Officer and 3 new VPs of Clinical Operations, Program and Alliance Management, and...
March 07, 2018 16:01 ET | Source: Acer Therapeutics Inc.

Acer Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update

NEWTON, Mass., March 07, 2018 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
March 06, 2018 08:30 ET | Source: Acer Therapeutics Inc.

Acer Therapeutics to Present at the 30th Annual ROTH Conference

NEWTON, Mass., March 06, 2018 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...